Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18663685 | 1.00 | CCR5 (0.32) | CCR5CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL18663745 | 1.00 | CCR5 (0.32) | CCR5CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL16893316 | 0.72 | — | — | |
| SCHEMBL18663772 | 0.70 | CHRNB2 (0.43) | CCR5CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL19189263 | 0.70 | CHRNB2 (0.43) | CCR5CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL25428547 | 0.70 | — | — | |
| SCHEMBL21460190 | 0.70 | CHRNB2 (0.43) | CCR5CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL17082823 | 0.70 | CHRNB2 (0.43) | CCR5CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL12350249 | 0.69 | — | — | |
| SCHEMBL22795640 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035766-B2 | Compositions for preventing and/or treating lysosomal storage disorders | AMICUS THERAPEUTICS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035766-B2 | Compositions for preventing and/or treating lysosomal storage disorders | GAA, GBA1, MAN2B1 | CCR5 4629/4885CHRNB2 2843/4885CHRNB4 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.